FLAMINAL® FOR THE TREATMENT OF OBESE PATIENTS WITH INFECTED WOUNDS

TINA DYBLE*, JENNIFER ASHTON**
*TISSUE VIABILITY NURSE SPECIALIST. EN, RGN, DIP HE, BSc MSC, **SENIOR STAFF NURSE. RGN, DIP HE. JAMES PAGET UNIVERSITY HOSPITAL NHS FOUNDATION TRUST. TEL: 01493 452299. E-MAIL: tina.dyble@jpaget.nhs.uk & jennifer.ashton@jpaget.nhs.uk

Introduction
Chronic leg ulceration affects up to 1% of the population1 and has been estimated at costing the NHS between £150-£600 million per year.7 Chronic leg ulceration in the obese patient is fast becoming a problem for the NHS as the number of obese patients increases year on year. One in four of all adults in England are now classed as obese2, with admissions to hospital in this client group rising from 2,215 in 2005 to 11,173 in 2010.3 Wound healing is often impaired within this group because they tend to suffer from a wide range of co-morbidities and are at an increased risk of developing a wound infection4 therefore obese patients can pose a significant challenge when it comes to wound care and product selection. Through a case study format with photographic evidence, the authors will describe the use and results of an antimicrobial product Flaminal® (Flen Pharma) which consists of naturally occurring enzymes and has the advantage of wider use in comparison to some other standard antimicrobials which may have limitations for some patient categories. communication describes the management of a self-inflicted wound and the use of an antimicrobial enzyme alginogel (Flaminal® Forte) to facilitate healing in a methicillin resistant Staphylococcus aureus (MRSA) positive wound without causing discomfort to the patient.

Method
Evaluation of Flaminal® performed was over a period of 6+ months. Photographs were taken at regular intervals with documentation recording the skin status during its use. Product evaluation forms were completed which encompassed ease of application, wear time, patient pain scale and effectiveness.

Patient A
• 56 year old female with chronic lymphedema and leg ulcers.
• Height 5’2, weight 33st, immobile and morbidly obese.
Patient A was admitted on the 10/1/11 with weeping cellulitis. Whilst her legs were being dressed twice daily with gamgee and bandages she was still having to wrap her legs with towels to manage the amount of exudate. She had superficial leg ulcers measuring approximately 40cm x 50cm, which extended the full length of her left lower leg. Pseudomonas and maceration were present and the granulation tissue was discoloured and friable.

A 5mm layer of Flaminal® Forte was applied to her ulcers and covered with Kerramax®. Chest pads were used to cover the entire leg and thigh with surgifix to secure. Dressings were initially reviewed daily but were tailored off as the exudate levels reduced.

Within 7 days of treatment the granulation tissue became less friable and more healthy in appearance. By day 18 the Pseudomonas and odour had resolved and the wound had reduced in size by nearly 50%. The exudate had subsided sufficiently to allow the dressings to be changed twice a week. The patient was discharged back into the community with the district nurses undertaking the dressings twice weekly.

Patient A
Admitted 10/1/11

Patient B's ERCP count was now low and therefore no antibiotics were prescribed. 4 days later the wound had islands of epithelial tissue and the exudate levels had subsided further.

Patient B
15/3/11

On follow up only a superficial area remained on the lateral side of her leg which measured approximately 10cm x 2.5cm.

Patient B
7/9/11

Continued overleaf...
Patient C
- 79 year old male, height 5' 9, weight 18st, no medical history other than morbid obesity and usually self caring for all ADLs.
- Patient C was admitted on the 30/5/11 with a query obstruction having suffered with vomiting for the past 4 days.
- On admission tests confirmed that he had severe constipation. He also presented with gangrene dressings from toe to knee on both legs which were so heavily saturated with fluid that the bed linen was also sodden. The dressings were foul smelling and green stained.

He had a large ulcer to his left leg measuring 22cm in length and the ulcer was painful to touch (ranked as level 7 using a Likert scale for pain).
- His right leg although ulcerated was less severe and while similarly treated has not been included in this case study. The district nurses had been visiting him daily for the past 2 years to redress his legs. They had used a multitude of products with the most recent being Sudocrem to the peri-wound area and absorbent alginate dressings to the ulcer. His legs were dressed with Flaminal® Forte and hydrofibre dressings and 1 week later, on the 4/7/11 the photographs showed that Patient C’s ulcers had reduced by over 70%

Compression therapy was maintained weekly by his community team with follow up appointments to the tissue viability department. Further photographs were taken on a weekly basis and within 2 weeks (27/6/11) Flaminal® Forte was no longer required.
- Foam dressings were used in place of Flaminal® Forte and hydrofibre dressings and 1 week later, on the 4/7/11 the ulcer was nearly healed.
- Exudate levels were under control and therefore as his main admission problem had now been resolved he was discharged home with follow up appointments to the tissue viability department.

Results
These case study findings highlight that Flaminal® Forte was able to manage exudate levels without causing further maceration. It controlled Pseudomomas and managed the patient’s pain related to dressing change as none of the patients within the study experienced any stinging or drawing sensation which is frequently associated with some other antimicrobials. This product is easy to apply and can be used in a variety of wound types.

Discussion
Flaminal® comes in a tube and is obtainable in the UK in two sizes, 15g and 50g.
- It is available in two formulations, Flaminal® Hydro which is suitable for low to moderate exuding wounds or Flaminal® Forte which is indicated for moderate to heavily exuding wounds. Unlike some other antimicrobials, Flaminal® has no reported evidence of cytotoxicity which offers an extended time frame of use and no limitations with the amount of product that can be used. The patients on which Flaminal® was evaluated all posed a significant challenge for successful wound management.

Conclusion
The authors conclude that Flaminal® is an effective alternative antimicrobial treatment to some traditional products whilst also being cost effective in comparison to other antimicrobial products. Flaminal® gave rapid results in all the study subjects which enabled early discharge. Early discharge is important as the longer obese patients are hospitalised, the risk of them becoming immobile and having further skin breakdown is increased.

Reference List

Flaminal® is a registered trademark of Flen Pharma
Kerramax® is a registered trademark of Crawford Healthcare
a. Registered trademark of Smith & Nephew
b. Registered trademark of Smith & Nephew
b. Registered trademark of Smith & Nephew
b. Registered trademark of Smith & Nephew
b. Registered trademark of Smith & Nephew
b. Registered trademark of Smith & Nephew
b. Registered trademark of Smith & Nephew
b. Registered trademark of Smith & Nephew
b. Registered trademark of Smith & Nephew